ODDO BHF
GERMAN INVESTMENT SEMINAR
JANUARY 11, 2022
Helen Giza - CFO
© Copyright
Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or might not even be anticipated. The Company has based these forward-looking statements on current estimates and assumptions which we believe are reasonable and which are made to the best of our knowledge. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) Annual Report on Form 20-F under the heading "Forward-Looking Statements" and under the headings in that report referred to therein, and in FMC AG & Co. KGaA's other reports filed with the Securities and Exchange Commission (SEC) and the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse).
Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.
If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in Euro if not mentioned otherwise.
Implementation of measures as presented herein may be subject to information & consultation procedures with works councils and other employee representative bodies, as per local laws and practice. Consultation procedures may lead to changes on proposed measures.
© Copyright
1 | |
2 | |
AGENDA | |
3 | |
4 | |
5 | |
AT A GLANCE
STRATEGY
MEDICAL UPDATE
BUSINESS UPDATE
FINANCIALS & OUTLOOK
9M 2021 | DELIVERING THE UPMOST QUALITY OF CARE
+2% Clinics | (1%) Patients | |
4,151 | 344,872 | |
(1%) Treatments | Quality remains | ||
on a consistently | |||
39,510,028 | |||
high level | |||
Clinics and patients as of September 30, 2021
Company Presentation | January 2022 | Page 4 |
FY 2020 | €17.9BN REVENUE
NORTH AMERICA | EMEA | ||||||||
Operating | Operating | ||||||||
Revenue | Patients | Clinics | Revenue | Patients | Clinics | ||||
Income | 70% | Income | 15% | ||||||
€12.5bn | €2,120m | ~210,300 | ~2,640 | of total | €2.8bn | €412m | ~66,000 | ~800 | of total |
revenue | revenue | ||||||||
+4%cc | +20%cc | 0% | +2% | +5%cc | (6)%cc | 0% | +3% | ||
LATIN AMERICA | ASIA-PACIFIC | |||||||||||
Operating | Operating | |||||||||||
Revenue | Patients | Clinics | 4% | 11% | ||||||||
Revenue | Patients | Clinics | ||||||||||
Income | Income | |||||||||||
€0.7bn | €(157)m | ~37,200 | ~250 | of total | of total | |||||||
revenue | €1.9bn | €344m | ~33,100 | ~400 | revenue | |||||||
+21%cc | n.a. | +7% | +6% | |||||||||
+3%cc | +5%cc | 0% | 0% | |||||||||
cc = at constant currency | ||||||||||||
Segment revenue and operating income FY 2020, number of patients and clinics as of YE 2020, yoy change | Service | Product | ||||||||||
revenue | revenue |
Company Presentation | January 2022 | Page 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
FMC - Fresenius Medical Care AG & Co. KGaA published this content on 11 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2022 10:35:05 UTC.